The study, which appears in the journal Pharmaceutical Research, investigated a new kind of antitumor chemical called RCn. When evaluated for its ability to kill cancer cells in mice, hospital researchers found RCn was more than 10 times more effective in eliminating tumor cells than regular cells, meaning the low dose necessary to impact cancerous cells will have minimal effect on normal cells, according to the researchers.
“This is particularly important for proving the safety of a potential therapy,” Timothy Cripe, MD, principal investigator on the research, said in a statement. The study authors are working to further test the capabilities of the new drug.
More articles on quality:
Regional differences in cancer treatment vary widely across Texas
Researchers create cancer-fighting bacteria
Providers don’t understand CT scan cancer risk, study suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
